Vericel Corp (VCEL)
47.83
-0.05
(-0.10%)
USD |
NASDAQ |
May 03, 16:00
47.81
-0.02
(-0.04%)
After-Hours: 20:00
Vericel Price to Book Value: 10.22 for May 3, 2024
Price to Book Value Chart
Historical Price to Book Value Data
Date | Value |
---|---|
May 03, 2024 | 10.22 |
May 02, 2024 | 10.23 |
May 01, 2024 | 10.06 |
April 30, 2024 | 9.803 |
April 29, 2024 | 9.974 |
April 26, 2024 | 9.842 |
April 25, 2024 | 9.714 |
April 24, 2024 | 9.855 |
April 23, 2024 | 9.921 |
April 22, 2024 | 9.699 |
April 19, 2024 | 9.348 |
April 18, 2024 | 9.374 |
April 17, 2024 | 9.887 |
April 16, 2024 | 10.16 |
April 15, 2024 | 10.41 |
April 12, 2024 | 10.24 |
April 11, 2024 | 10.41 |
April 10, 2024 | 10.51 |
April 09, 2024 | 10.76 |
April 08, 2024 | 10.74 |
April 05, 2024 | 10.91 |
April 04, 2024 | 10.78 |
April 03, 2024 | 10.97 |
April 02, 2024 | 10.96 |
April 01, 2024 | 11.31 |
Date | Value |
---|---|
March 28, 2024 | 11.12 |
March 27, 2024 | 11.18 |
March 26, 2024 | 10.59 |
March 25, 2024 | 10.25 |
March 22, 2024 | 10.02 |
March 21, 2024 | 9.978 |
March 20, 2024 | 9.778 |
March 19, 2024 | 9.752 |
March 18, 2024 | 9.444 |
March 15, 2024 | 9.459 |
March 14, 2024 | 9.448 |
March 13, 2024 | 9.513 |
March 12, 2024 | 9.489 |
March 11, 2024 | 9.530 |
March 08, 2024 | 9.660 |
March 07, 2024 | 9.579 |
March 06, 2024 | 9.656 |
March 05, 2024 | 9.502 |
March 04, 2024 | 9.568 |
March 01, 2024 | 9.555 |
February 29, 2024 | 9.763 |
February 28, 2024 | 10.22 |
February 27, 2024 | 10.26 |
February 26, 2024 | 10.28 |
February 23, 2024 | 10.11 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
2.933
Minimum
Mar 18 2020
22.42
Maximum
Jun 28 2021
9.436
Average
8.166
Median
Nov 01 2023
Price to Book Value Benchmarks
ANI Pharmaceuticals Inc | 3.274 |
Arbutus Biopharma Corp | 4.606 |
Chimerix Inc | 0.4404 |
Karyopharm Therapeutics Inc | -- |
Y-mAbs Therapeutics Inc | 7.451 |
Price to Book Value Related Metrics
PS Ratio | 11.52 |
Price to Free Cash Flow | 291.89 |
Price | 47.83 |
Earnings Yield | -0.17% |
Market Cap | 2.310B |